Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 16, 2026
DataAggregated Company Financials
Companies150
  • 7D0.2%
  • 3M-5.1%
  • 1Y-6.3%
  • YTD-5.5%

Over the last 7 days, the Healthcare industry has remained flat, although notably Sectra gained 9.5%. As for the longer term, the industry has declined 6.3% in the last year. Earnings are forecast to grow by 25% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 18 Mar 2026SEK 551.4bSEK 228.9b-SEK 2,899,721,423.9230.3x-190.2x2.4x
Fri, 13 Feb 2026SEK 558.8bSEK 230.1b-SEK 1,683,582,565.1631.8x-331.9x2.4x
Sun, 11 Jan 2026SEK 599.8bSEK 230.2bSEK 3.7b41x163.5x2.6x
Tue, 09 Dec 2025SEK 591.0bSEK 230.7bSEK 3.5b41.7x166.5x2.6x
Thu, 06 Nov 2025SEK 591.0bSEK 228.3bSEK 2.5b44.4x235.9x2.6x
Sat, 04 Oct 2025SEK 614.2bSEK 227.1bSEK 6.6b43.2x93x2.7x
Mon, 01 Sep 2025SEK 623.6bSEK 227.3bSEK 6.6b46.8x94.9x2.7x
Wed, 30 Jul 2025SEK 649.0bSEK 226.8bSEK 6.5b55.9x99.2x2.9x
Fri, 27 Jun 2025SEK 605.8bSEK 226.8bSEK 5.9b44.9x103.5x2.7x
Sun, 25 May 2025SEK 587.2bSEK 226.0bSEK 6.6b37x88.8x2.6x
Tue, 22 Apr 2025SEK 548.1bSEK 221.4bSEK 5.2b33.6x106.2x2.5x
Thu, 20 Mar 2025SEK 558.2bSEK 206.3bSEK 5.0b37.3x111.9x2.7x
Sat, 15 Feb 2025SEK 594.9bSEK 206.4bSEK 2.5b41.7x235.5x2.9x
Mon, 13 Jan 2025SEK 581.1bSEK 201.5b-SEK 2,657,438,736.2740.7x-218.7x2.9x
Wed, 11 Dec 2024SEK 572.8bSEK 202.6b-SEK 2,457,579,486.5337.9x-233.1x2.8x
Fri, 08 Nov 2024SEK 524.8bSEK 199.9b-SEK 2,617,639,492.4737.5x-200.5x2.6x
Sun, 06 Oct 2024SEK 607.5bSEK 200.2b-SEK 2,782,910,611.7639.8x-218.3x3x
Tue, 03 Sep 2024SEK 611.2bSEK 200.0b-SEK 2,803,888,083.8842.3x-218x3.1x
Thu, 01 Aug 2024SEK 592.1bSEK 199.7b-SEK 2,762,731,708.4442.1x-214.3x3x
Sat, 29 Jun 2024SEK 561.9bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Mon, 27 May 2024SEK 553.7bSEK 196.1b-SEK 2,796,375,625.7836.5x-198x2.8x
Wed, 24 Apr 2024SEK 521.9bSEK 193.3b-SEK 3,279,840,759.5643.7x-159.1x2.7x
Fri, 22 Mar 2024SEK 523.2bSEK 192.5b-SEK 3,668,734,466.5344.4x-142.6x2.7x
Sun, 18 Feb 2024SEK 516.9bSEK 191.7b-SEK 4,080,444,504.7249.9x-126.7x2.7x
Tue, 16 Jan 2024SEK 548.3bSEK 191.5b-SEK 966,049,928.0048x-567.5x2.9x
Thu, 14 Dec 2023SEK 503.9bSEK 191.3b-SEK 1,013,947,502.0047x-497x2.6x
Sat, 11 Nov 2023SEK 470.7bSEK 190.3b-SEK 1,053,916,718.0049.4x-446.6x2.5x
Mon, 09 Oct 2023SEK 447.6bSEK 185.1b-SEK 2,032,952,939.0034.3x-220.2x2.4x
Wed, 06 Sep 2023SEK 460.4bSEK 185.6b-SEK 2,036,613,372.0037.8x-226x2.5x
Fri, 04 Aug 2023SEK 472.0bSEK 184.0b-SEK 1,006,517,861.0039.1x-469x2.6x
Sun, 02 Jul 2023SEK 480.3bSEK 179.2b-SEK 795,007,793.0044.7x-604.2x2.7x
Tue, 30 May 2023SEK 510.8bSEK 178.7b-SEK 546,541,263.0043.5x-934.5x2.9x
Thu, 27 Apr 2023SEK 511.7bSEK 173.4b-SEK 1,511,475,397.0034.2x-338.5x3x
Sat, 25 Mar 2023SEK 482.3bSEK 172.4b-SEK 1,417,053,012.0035.3x-340.4x2.8x
Price to Earnings Ratio

-340.4x


Total Market Cap: SEK 482.3bTotal Earnings: -SEK 1,417,053,012.00Total Revenue: SEK 172.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -166x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.51%
Healthcare0.18%
Healthtech7.53%
Biotech0.16%
Healthcare Services-0.20%
Life Sciences-0.59%
Pharma-1.02%
Medical Equipment-1.86%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 115x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VIMIAN Vimian GroupSEK 27.084.3%
+SEK 592.8m		-28.5%PE42.8x
MVIR MedivirSEK 2.6567.4%
+SEK 573.7m		76.9%PS167.6x
SECT B SectraSEK 226.801.3%
+SEK 539.5m		-10.0%PE81.3x
BIOG B BioGaiaSEK 115.503.5%
+SEK 394.5m		-1.2%PE35.1x
DICOT Dicot PharmaSEK 0.4854.2%
+SEK 338.6m		80.6%PB13.1x

Latest News

BONEX
SEK 190.00
Bonesupport Holding
7D
-5.3%
1Y
-41.2%

Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix

Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?
GETI B
SEK 189.60
Getinge
7D
-2.7%
1Y
-14.8%

GETI B: Slightly Higher Dividend Will Still Leave P/E Looking Stretched

Analysts have kept their SEK 170.97 price target for Getinge broadly unchanged, citing only marginal tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view of the shares. What's in the News Getinge AB has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 previously (Key Developments).
MVIR
SEK 2.65
Medivir
7D
67.4%
1Y
76.9%

Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story

Catalysts About Medivir Medivir is a research based pharmaceutical company focused on developing first in class therapies for oncology and rare bone disorders. What are the underlying business or industry changes driving this perspective?
SECT B
SEK 226.80
Sectra
7D
1.3%
1Y
-10.0%
ATT
SEK 101.80
Attendo
7D
-1.5%
1Y
61.3%

ATT: Future Dividend And Cash Returns Will Support Steady Prospects

Narrative Update on Attendo Analysts have kept Attendo's fair value estimate steady at SEK 110, with only minor adjustments to inputs such as the discount rate and assumed future P/E. This reflects fine tuning of their valuation rather than a shift in overall view.
XVIVO
SEK 187.80
Xvivo Perfusion
7D
2.1%
1Y
-54.9%

XVIVO: Higher Growth Assumptions Will Support Continued Bullish Repricing

Analysts now set their price target for Xvivo Perfusion at SEK301.0, compared with the prior SEK316.6, reflecting updated assumptions around slightly higher revenue growth, a lower profit margin, a higher discount rate, and a modestly higher future P/E multiple. Valuation Changes Fair Value: SEK316.6 has been revised to SEK301.0, a modest reduction in the estimated valuation level.
MCOV B
SEK 197.40
Medicover
7D
-5.6%
1Y
1.2%

MCOV B: Dividend Uplift And 2028 Revenue Ambition Will Support Future Upside

Analysts have kept their price target for Medicover broadly unchanged at around SEK 257, reflecting stable assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News The board of Medicover AB proposes a dividend of SEK 0.20 per share for the financial year 2025, compared with SEK 0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
SOBI
SEK 382.60
Swedish Orphan Biovitrum
7D
-1.5%
1Y
33.2%

SOBI: Kidney And Sepsis Advances Will Support A More Upbeat Outlook

The analyst fair value estimate for Swedish Orphan Biovitrum has been adjusted from SEK 416 to SEK 424, reflecting recent price target increases to SEK 470 and SEK 500, as well as updated analyst views on revenue growth, margins and future P/E assumptions. Analyst Commentary Recent Street research on Swedish Orphan Biovitrum presents a mix of optimism and caution around the shares, which helps frame the updated fair value estimate of SEK 424.
EKTA B
SEK 57.80
Elekta
7D
-4.7%
1Y
0.2%
BIOG B
SEK 115.50
BioGaia
7D
3.5%
1Y
-1.2%

BIOG B: Extra Dividend And Solid Margins Will Support Higher Earnings Multiple

Analysts have maintained their SEK 140.0 fair value estimate for BioGaia, citing only minor adjustments to the discount rate and to long-term assumptions on revenue growth, profit margins and future P/E as the basis for keeping their price target unchanged. What's in the News BioGaia renewed and extended its distribution agreement with Ewopharma, which will now distribute a broad range of BioGaia products in more than 15 European countries, with a focus on Central Eastern Europe and Switzerland (Key Developments).
VIMIAN
SEK 27.08
Vimian Group
7D
4.3%
1Y
-28.5%

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
CAMX
SEK 471.00
Camurus
7D
-2.3%
1Y
-20.6%

CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential

Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
CRNO B
SEK 6.49
Cereno Scientific
7D
14.1%
1Y
23.6%
IMP A SDB
SEK 40.05
Implantica
7D
-3.7%
1Y
29.0%
DICOT
SEK 0.48
Dicot Pharma
7D
54.2%
1Y
80.6%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%